Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impaired phagocytic capacity driven by downregulation of major phagocytosis-related cell surface molecules elicits an overall modulatory cytokine profile in neutrophils and monocytes from the indeterminate clinical form of Chagas disease.
Gomes JA, Campi-Azevedo AC, Teixeira-Carvalho A, Silveira-Lemos D, Vitelli-Avelar D, Sathler-Avelar R, Peruhype-Magalhães V, Silvestre KF, Batista MA, Schachnik NC, Correa-Oliveira R, Eloi-Santos S, Martins-Filho OA. Gomes JA, et al. Immunobiology. 2012 Oct;217(10):1005-16. doi: 10.1016/j.imbio.2012.01.014. Epub 2012 Jan 20. Immunobiology. 2012. PMID: 22387073
Benznidazole treatment during early-indeterminate Chagas' disease shifted the cytokine expression by innate and adaptive immunity cells toward a type 1-modulated immune profile.
Sathler-Avelar R, Vitelli-Avelar DM, Massara RL, Borges JD, Lana M, Teixeira-Carvalho A, Dias JC, Elói-Santos SM, Martins-Filho OA. Sathler-Avelar R, et al. Scand J Immunol. 2006 Nov;64(5):554-63. doi: 10.1111/j.1365-3083.2006.01843.x. Scand J Immunol. 2006. PMID: 17032249 Free article. Clinical Trial.
Etiological treatment of Chagas disease patients with benznidazole lead to a sustained pro-inflammatory profile counterbalanced by modulatory events.
Campi-Azevedo AC, Gomes JA, Teixeira-Carvalho A, Silveira-Lemos D, Vitelli-Avelar DM, Sathler-Avelar R, Peruhype-Magalhães V, Béla SR, Silvestre KF, Batista MA, Schachnik NC, Correa-Oliveira R, Eloi-Santos SM, Martins-Filho OA. Campi-Azevedo AC, et al. Among authors: vitelli avelar dm. Immunobiology. 2015 May;220(5):564-74. doi: 10.1016/j.imbio.2014.12.006. Epub 2015 Jan 8. Immunobiology. 2015. PMID: 25648688
Systems Biology Reveals Relevant Gaps in Fc-γR Expression, Impaired Regulatory Cytokine Microenvironment Interfaced With Anti-Trypanosoma cruzi IgG Reactivity in Cardiac Chagas Disease Patients.
Gomes JAS, de Araújo FF, Vitelli-Avelar DM, Sathler-Avelar R, Lage PS, Wendling APB, do Vale INPC, Dias JCP, Elói-Santos SM, Teixeira-Carvalho A, Martins-Filho OA. Gomes JAS, et al. Among authors: vitelli avelar dm. Front Microbiol. 2018 Jul 30;9:1608. doi: 10.3389/fmicb.2018.01608. eCollection 2018. Front Microbiol. 2018. PMID: 30105007 Free PMC article.
Chagasic patients with indeterminate clinical form of the disease have high frequencies of circulating CD3+CD16-CD56+ natural killer T cells and CD4+CD25High regulatory T lymphocytes.
Vitelli-Avelar DM, Sathler-Avelar R, Dias JC, Pascoal VP, Teixeira-Carvalho A, Lage PS, Elói-Santos SM, Corrêa-Oliveira R, Martins-Filho OA. Vitelli-Avelar DM, et al. Scand J Immunol. 2005 Sep;62(3):297-308. doi: 10.1111/j.1365-3083.2005.01668.x. Scand J Immunol. 2005. PMID: 16179017 Free article.
Are increased frequency of macrophage-like and natural killer (NK) cells, together with high levels of NKT and CD4+CD25high T cells balancing activated CD8+ T cells, the key to control Chagas' disease morbidity?
Vitelli-Avelar DM, Sathler-Avelar R, Massara RL, Borges JD, Lage PS, Lana M, Teixeira-Carvalho A, Dias JC, Elói-Santos SM, Martins-Filho OA. Vitelli-Avelar DM, et al. Clin Exp Immunol. 2006 Jul;145(1):81-92. doi: 10.1111/j.1365-2249.2006.03123.x. Clin Exp Immunol. 2006. PMID: 16792677 Free PMC article.
Persistence of PCR-positive tissue in benznidazole-treated mice with negative blood parasitological and serological tests in dual infections with Trypanosoma cruzi stocks from different genotypes.
Martins HR, Figueiredo LM, Valamiel-Silva JC, Carneiro CM, Machado-Coelho GL, Vitelli-Avelar DM, Bahia MT, Martins-Filho OA, Macedo AM, Lana M. Martins HR, et al. J Antimicrob Chemother. 2008 Jun;61(6):1319-27. doi: 10.1093/jac/dkn092. Epub 2008 Mar 13. J Antimicrob Chemother. 2008. PMID: 18343804
Impact of dual infections on chemotherapeutic efficacy in BALB/c mice infected with major genotypes of Trypanosoma cruzi.
Martins HR, Silva RM, Valadares HM, Toledo MJ, Veloso VM, Vitelli-Avelar DM, Carneiro CM, Machado-Coelho GL, Bahia MT, Martins-Filho OA, Macedo AM, Lana M. Martins HR, et al. Antimicrob Agents Chemother. 2007 Sep;51(9):3282-9. doi: 10.1128/AAC.01590-06. Epub 2007 Jul 16. Antimicrob Agents Chemother. 2007. PMID: 17638698 Free PMC article.
Dissimilar Trypanosoma cruzi genotype-specific serological profile assessed by Chagas-Flow ATE IgG1 upon benznidazole etiological treatment of chronic Chagas disease.
Alessio GD, Silvestrini CMA, Elói-Santos SM, Gontijo ED, Sales Júnior PA, Vitelli-Avelar DM, Sathler-Avelar R, Wendling APB, Teixeira-Carvalho A, de Lana M, Martins-Filho OA. Alessio GD, et al. Among authors: vitelli avelar dm. PLoS Negl Trop Dis. 2024 Sep 13;18(9):e0012487. doi: 10.1371/journal.pntd.0012487. eCollection 2024 Sep. PLoS Negl Trop Dis. 2024. PMID: 39269987 Free PMC article.
26 results